Thomas M. Roberts

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism

Jing Chen, Katsunori Fujii, H. Fu, 2001, Proceedings of the National Academy of Sciences of the United States of America.

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy

Pixu Liu, Hailing Cheng, T. Roberts, 2017, Oncogene.

Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate

D. Morrison, H. Piwnica-Worms, D. Beach, 1988, Nature.

Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.

N. Gray, Qingsong Liu, C. Benes, 2012, Cancer discovery.

The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase

L. Cantley, D. Morrison, L. Varticovski, 1989, Nature.

Oridonin inhibits aberrant AKT activation in breast cancer

J. Clardy, H. Cheung, Jean J. Zhao, 2018, Oncotarget.

PI3Kβ controls immune evasion in PTEN-deficient breast tumours

G. Freeman, S. Prakadan, A. Shalek, 2023, Nature.

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

U. Matulonis, Shaozhen Xie, P. Konstantinopoulos, 2023, Journal for ImmunoTherapy of Cancer.

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers

E. Winer, J. Spangle, N. Lin, 2016, Oncogene.